Mechanisms of Particulate Matter Induced Dendritic Cell Activation

颗粒物诱导树突状细胞激活的机制

基本信息

  • 批准号:
    8294888
  • 负责人:
  • 金额:
    $ 53.39万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-07-01 至 2014-06-30
  • 项目状态:
    已结题

项目摘要

Numerous studies have shown a strong association between exposure to airborne particulate matter (PM) and indicators of asthma. However, the mechanisms underlying this association remain unknown. Utilizing murine strains of mice, we have demonstrated that exposure to real world particulate matter induces allergic responses in some strains (A/J) of mice, while not in others (C3H/HeJ). Our preliminary studies suggest that PM exposure may confer susceptibility to asthma symptoms by altering dendritic cell (DC) phenotype and function. Specifically, we have made the novel observation that PM alters the relative proportion of immunogenic myeloid DC to tolerogenic plasmacytoid DC recruited to the lungs of susceptible A/J mice. Although the mechanisms by which AUB regulates DC function are unknown, our preliminary data suggests the following hypothesis: that ambient PM induces the allergic response via activation of dendritic cells through synergistic oxidant and pattern recognition receptor- dependent (PRRs) pathways. To test this hypothesis, we propose the following aims: 1) To determine the molecular mechanisms by which PM-induces epithelial cell chemokine production and DC recruitment, we will test the hypothesis that PM induces epithelial cell chemokine production and DC recruitment and maturation via oxidative stress pathways; 2) To determine the exact mechanisms by which PM alters DC cell phenotype, maturation and T cell stimulatory ability in vitro, we will evaluate the contribution of oxidative stress and pattern recognition receptor pathways (TLRs and dectin-1) to PM- induced alterations in DC phenotype (DC subset, costimulatory molecule expression, cytokine production, stimulation of CD4+T cells) in susceptible and resistant murine strains using a combination of approaches (i.e. pharmacological inhibitors, genetically engineered mice); and 3) To determine the contribution of AUB-activated DC subsets to susceptibility to the development of allergic airway responses in murine strains (A/J, C3H) in vivo, we will test the hypothesis that genetic differences in activation of oxidant and/or pattern recognition receptors (TLRs, dectin-1) contribute to altered activation of DC and subsequent development of the AUB-induced allergic phenotype. Taken together with the results of the other projects, the results of this proposal will provide a better understanding of how exposures to environmental particulate matter may exacerbate and/or induce airway inflammation and respiratory morbidity with the ultimate goal of translation of information into clinical applications or intervention strategies that can be used to reduce the morbidity of childhood asthma.
许多研究表明,暴露于空气中的颗粒物 (PM)和哮喘的症状然而,这种关联的机制仍然未知。 利用小鼠品系,我们已经证明,暴露于真实的世界颗粒物, 在某些品系的小鼠(A/J)中诱导过敏反应,而在另一些品系的小鼠(C3 H/HeJ)中不诱导过敏反应。我们的初步 研究表明,PM暴露可能通过改变树突状细胞而赋予哮喘症状的易感性, (DC)表型和功能。具体来说,我们已经作出了新的观察,PM改变了 免疫原性髓样DC与致耐受性浆细胞样DC募集到肺的相对比例 易感A/J小鼠。虽然AUB调节DC功能的机制尚不清楚,但我们的研究表明, 初步数据表明,以下假设:环境PM诱导过敏反应,通过 通过协同氧化剂和模式识别受体激活树突状细胞- 依赖性(PRRs)途径。为了验证这一假设,我们提出了以下目标:1)确定 PM诱导上皮细胞产生趋化因子和DC的分子机制 招募,我们将测试的假设,PM诱导上皮细胞趋化因子的生产和DC 通过氧化应激途径招募和成熟; 2)通过以下方法确定确切机制: PM在体外改变DC细胞表型、成熟和T细胞刺激能力, 氧化应激和模式识别受体途径(TLR和dectin-1)对PM的贡献- 诱导DC表型(DC亚群、共刺激分子表达、细胞因子 产生、刺激CD 4 +T细胞)在敏感和抗性鼠品系中使用以下的组合 方法(即药理学抑制剂,基因工程小鼠);和3)为了确定 AUB激活的DC亚群对过敏性气道形成易感性的作用 在小鼠品系(A/J,C3 H)的体内反应中,我们将检验以下假设: 氧化剂和/或模式识别受体(TLR,dectin-1)的激活有助于改变激活 的DC和随后的AUB诱导的过敏性表型的发展。再加上 其他项目的结果,本提案的结果将提供一个更好的了解如何 暴露于环境颗粒物质可加剧和/或诱发气道炎症, 呼吸系统疾病,最终目标是将信息转化为临床应用,或 可用于降低儿童哮喘发病率的干预策略。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Marsha Wills-Karp其他文献

Marsha Wills-Karp的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Marsha Wills-Karp', 18)}}的其他基金

Administrative Core
行政核心
  • 批准号:
    10652257
  • 财政年份:
    2022
  • 资助金额:
    $ 53.39万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10394476
  • 财政年份:
    2022
  • 资助金额:
    $ 53.39万
  • 项目类别:
Center for Community Health: Addressing Regional Maryland Environmental Determinants of Disease
社区健康中心:解决马里兰州地区疾病的环境决定因素
  • 批准号:
    10652256
  • 财政年份:
    2022
  • 资助金额:
    $ 53.39万
  • 项目类别:
Center for Community Health: Addressing Regional Maryland Environmental Determinants of Disease
社区健康中心:解决马里兰州地区疾病的环境决定因素
  • 批准号:
    10394475
  • 财政年份:
    2022
  • 资助金额:
    $ 53.39万
  • 项目类别:
18th International Congress of Mucosal Immunology (ICMI 2017)
第十八届国际粘膜免疫学大会(ICMI 2017)
  • 批准号:
    9398538
  • 财政年份:
    2017
  • 资助金额:
    $ 53.39万
  • 项目类别:
MoFlo XDP Cell Sorter
MoFlo XDP 细胞分选仪
  • 批准号:
    8052296
  • 财政年份:
    2011
  • 资助金额:
    $ 53.39万
  • 项目类别:
Role of allergen-driven epithelial genes in asthma pathogenesis
过敏原驱动的上皮基因在哮喘发病机制中的作用
  • 批准号:
    8196246
  • 财政年份:
    2011
  • 资助金额:
    $ 53.39万
  • 项目类别:
Epithelial Regulation of Th2 Immune Responses in the Lung
肺中 Th2 免疫反应的上皮调节
  • 批准号:
    8443938
  • 财政年份:
    2009
  • 资助金额:
    $ 53.39万
  • 项目类别:
Epithelial Regulation of Th2 Immune Responses in the Lung
肺中 Th2 免疫反应的上皮调节
  • 批准号:
    8509573
  • 财政年份:
    2009
  • 资助金额:
    $ 53.39万
  • 项目类别:
Epithelial Regulation of Th2 Immune Responses in the Lung
肺中 Th2 免疫反应的上皮调节
  • 批准号:
    7696785
  • 财政年份:
    2009
  • 资助金额:
    $ 53.39万
  • 项目类别:

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 53.39万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 53.39万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 53.39万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 53.39万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 53.39万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 53.39万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 53.39万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 53.39万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 53.39万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 53.39万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了